ReviewAging clinical and experimental research2026
Aging in Behçet's syndrome: an overlooked risk for late-life cognitive impairment.
Review in Aging clinical and experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's syndrome (BS) is a chronic multisystemic inflammatory disorder with a heterogeneous clinical course. A severe subset with central nervous system involvement (neuro-Behçet's syndrome, NBS) carries substantial morbidity. While disease activity often decreases with age, the long-term neurological and cognitive outcomes remain poorly defined. Emerging evidence indicates that vascular insufficiency, chronic inflammation, and central nervous system involvement may contribute to cognitive decline in BS, even in the absence of frank neurological symptoms, suggesting a broader and underrecognized impact on brain function. These processes overlap with mechanisms implicated in age-related cognitive decline and dementia, bringing up the hypothesis that BS may accelerate neurodegenerative trajectories in older adults. However, this population remains underrepresented in research. Clarifying whether BS constitutes an overlooked cause or modifier of late-life cognitive decline is clinically urgent. A coordinated agenda spanning neuropsychology, advanced imaging, and biomarkers can deliver diagnostic pathways and testable prevention/management strategies for aging BS populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.